Roche's experimental RNA drug sefaxersen significantly reduced proteinuria in a late-stage trial for IgA nephropathy, positioning the company to bring a new treatment to market for the autoimmune kidney disease that currently has limited approved therapies.
Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe Sjögren's disease, a chronic autoimmune condition with no currently approved therapies. The drug was acquired through Amgen's $28 billion Horizon Therapeutics buyout.
Teva's experimental drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge in a mid-stage study, representing potential progress for a condition with no current drug treatments.
Novartis temporarily halted enrollment and treatment in eight clinical trials of an experimental CAR-T therapy for autoimmune and neurological disorders in late August after three patients died. Bristol Myers Squibb programs were also paused.
The European Medicines Agency recommended withdrawing marketing authorization for Amgen's rare autoimmune disease drug Tavneos, citing allegedly incorrect and misleading data used in the approval process and lack of benefits outweighing risks.
Five years after initial lupus breakthrough, CAR-T cell therapy continues to demonstrate remissions in autoimmune diseases, generating significant research investment and experimentation beyond its original cancer applications.
Scripps Research scientists have developed a first-in-class drug compound that reduces harmful inflammation while leaving the body's ability to fight infections intact, addressing a long-sought goal in treating autoimmune diseases.
